デフォルト表紙
市場調査レポート
商品コード
1487627

HER2抗体市場：世界の産業分析、規模、シェア、成長、動向、2024-2034年予測

HER2 Antibodies Market (Type of Treatment Drugs: Trastuzumab, Lapatinib, Ado-trastuzumab Emtansine, Pertuzumab, and Everolimus) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2024-2034

出版日
ページ情報
英文 112 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.10円
HER2抗体市場：世界の産業分析、規模、シェア、成長、動向、2024-2034年予測
出版日: 2024年04月15日
発行: Transparency Market Research
ページ情報: 英文 112 Pages
納期: 2～10営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 図表
  • 目次
概要

HER2抗体市場- 調査範囲

TMRの調査レポート「世界のHER2抗体市場」は、2024年から2034年までの予測期間における市場の指標に関する貴重な洞察を得るため、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2024年を基準年、2034年を予測年として、2018年から2034年までの世界のHER2抗体市場の収益を提供しています。また、2024年から2034年までの世界のHER2抗体市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されました。1次調査では、主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、HER2抗体市場を理解するために、主要企業の製品資料、年次報告書、プレスリリース、関連文書を参照しました。

市場スナップショット
2023年の市場規模 90億米ドル
2034年の市場価値 157億米ドル
CAGR 5.1%

本レポートでは、世界のHER2抗体市場の競合情勢について掘り下げています。世界のHER2抗体市場で事業を展開する主要企業が特定され、各企業が様々な属性でプロファイルされています。企業概要、財務状況、最近の動向、SWOTは、本レポートで紹介されている世界のHER2抗体市場におけるプレイヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 市場概要
  • 市場力学
  • 世界市場の分析と予測、2020-2034年

第5章 主要洞察

  • パイプライン分析
  • 主要製品/ブランド分析
  • 主要M&A
  • COVID-19パンデミックの産業への影響

第6章 世界市場分析と予測：治療薬タイプ別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：治療薬タイプ別、2020年～2034年
    • トラスツズマブ
    • ラパチニブ
    • アドトラスツズマブエムタンシン
    • ペルツズマブ
    • エベロリムス
  • 市場魅力度分析：治療薬タイプ別

第7章 世界市場分析・予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別, 2020-2034
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力度分析：地域別

第8章 北米市場の分析と予測

第9章 欧州市場の分析と予測

第10章 アジア太平洋市場の分析と予測

第11章 ラテンアメリカ市場の分析と予測

第12章 中東・アフリカ市場の分析と予測

第13章 競合情勢

  • 市場競合マトリックス（企業階層別・企業規模別）
  • 市場シェア分析：企業別（2023年）
  • 企業プロファイル
    • Novartis AG
    • Pfizer, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Abnova Corporation
    • InvivoGen
    • Celltrion, Inc.
    • Biocon
    • Novus Biologicals
図表

List of Tables

  • Table 01: Global HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2020-2034
  • Table 02: Global HER2 Antibodies Market Size (US$ Mn) Forecast, by Region, 2020-2034
  • Table 03: North America HER2 Antibodies Market Size (US$ Mn) Forecast, by Country, 2020-2034
  • Table 04: North America HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2020-2034
  • Table 05: Europe HER2 Antibodies Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 06: Europe HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2020-2034
  • Table 07: Asia Pacific HER2 Antibodies Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 08: Asia Pacific HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2020-2034
  • Table 09: Latin America HER2 Antibodies Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 10: Latin America HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2020-2034
  • Table 11: Middle East & Africa HER2 Antibodies Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 12: Middle East & Africa HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2020-2034

List of Figures

  • Figure 01: Global HER2 Antibodies Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2034
  • Figure 02: Global HER2 Antibodies Market Revenue (US$ Mn), by Type of Treatment Drugs, 2023
  • Figure 03: Global HER2 Antibodies Market Value Share, by Type of Treatment Drugs, 2023
  • Figure 04: Global HER2 Antibodies Market Value Share, by Region, 2023
  • Figure 05: Global HER2 Antibodies Market Value (US$ Mn) Forecast, 2024-2034
  • Figure 06: Global HER2 Antibodies Market Value Share Analysis, by Type of Treatment Drugs, 2023 and 2034
  • Figure 07: Global HER2 Antibodies Market Attractiveness Analysis, by Type of Treatment Drugs, 2024-2034
  • Figure 08: Global HER2 Antibodies Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 09: Global HER2 Antibodies Market Attractiveness Analysis, by Region, 2023-2034
  • Figure 10: North America HER2 Antibodies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 11: North America HER2 Antibodies Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 12: North America HER2 Antibodies Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 13: North America HER2 Antibodies Market Value Share Analysis, by Type of Treatment Drugs, 2023 and 2034
  • Figure 14: North America HER2 Antibodies Market Attractiveness Analysis, by Type of Treatment Drugs, 2024-2034
  • Figure 15: Europe HER2 Antibodies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 16: Europe HER2 Antibodies Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 17: Europe HER2 Antibodies Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 18: Europe HER2 Antibodies Market Value Share Analysis, by Type of Treatment Drugs, 2023 and 2034
  • Figure 19: Europe HER2 Antibodies Market Attractiveness Analysis, by Type of Treatment Drugs, 2024-2034
  • Figure 20: Asia Pacific HER2 Antibodies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 21: Asia Pacific HER2 Antibodies Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 22: Asia Pacific HER2 Antibodies Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 23: Asia Pacific HER2 Antibodies Market Value Share Analysis, by Type of Treatment Drugs, 2023 and 2034
  • Figure 24: Asia Pacific HER2 Antibodies Market Attractiveness Analysis, by Type of Treatment Drugs, 2024-2034
  • Figure 25: Latin America HER2 Antibodies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 26: Latin America HER2 Antibodies Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 27: Latin America HER2 Antibodies Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 28: Latin America HER2 Antibodies Market Value Share Analysis, by Type of Treatment Drugs, 2023 and 2034
  • Figure 29: Latin America HER2 Antibodies Market Attractiveness Analysis, by Type of Treatment Drugs, 2024-2034
  • Figure 30: Middle East & Africa HER2 Antibodies Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 31: Middle East & Africa HER2 Antibodies Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 32: Middle East & Africa HER2 Antibodies Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 33: Middle East & Africa HER2 Antibodies Market Value Share Analysis, by Type of Treatment Drugs, 2023 and 2034
  • Figure 34: Middle East & Africa HER2 Antibodies Market Attractiveness Analysis, by Type of Treatment Drugs, 2024-2034
目次
Product Code: TMRGL7301

HER2 Antibodies Market - Scope of Report

TMR's report on the global HER2 antibodies market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global HER2 antibodies market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global HER2 antibodies market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the HER2 antibodies market.

Market Snapshot
Market Value in 2023US$ 9 Bn
Market Value in 2034US$ 15.7 Bn
CAGR5.1%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global HER2 antibodies market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global HER2 antibodies market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global HER2 antibodies market.

The report delves into the competitive landscape of the global HER2 antibodies market. Key players operating in the global HER2 antibodies market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global HER2 antibodies market profiled in this report.

Key Questions Answered in Global HER2 antibodies Market Report:

  • What is the sales/revenue generated by HER2 antibodies across all regions during the forecast period?
  • What are the opportunities in the global HER2 antibodies market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

HER2 Antibodies Market - Research Objectives and Research Approach

The comprehensive report on the global HER2 antibodies market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global HER2 antibodies market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global HER2 antibodies market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global HER2 Antibodies Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global HER2 Antibodies Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global HER2 Antibodies Market Analysis and Forecast, by Type of Treatment Drugs

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Type of Treatment Drugs, 2020-2034
    • 6.3.1. Trastuzumab
    • 6.3.2. Lapatinib
    • 6.3.3. Ado-trastuzumab Emtansine
    • 6.3.4. Pertuzumab
    • 6.3.5. Everolimus
  • 6.4. Market Attractiveness Analysis, by Type of Treatment Drugs

7. Global HER2 Antibodies Market Analysis and Forecast, by Region

  • 7.1. Key Findings
  • 7.2. Market Value Forecast, by Region, 2020-2034
    • 7.2.1. North America
    • 7.2.2. Europe
    • 7.2.3. Asia Pacific
    • 7.2.4. Latin America
    • 7.2.5. Middle East & Africa
  • 7.3. Market Attractiveness Analysis, by Region

8. North America HER2 Antibodies Market Analysis and Forecast

  • 8.1. Introduction
  • 8.2. Key Findings
  • 8.3. Market Value Forecast, by Type of Treatment Drugs, 2020-2034
    • 8.3.1. Trastuzumab
    • 8.3.2. Lapatinib
    • 8.3.3. Ado-trastuzumab Emtansine
    • 8.3.4. Pertuzumab
    • 8.3.5. Everolimus
  • 8.4. Market Value Forecast, by Country, 2020-2034
    • 8.4.1. U.S.
    • 8.4.2. Canada
  • 8.5. Market Attractiveness Analysis
    • 8.5.1. By Type of Treatment Drugs
    • 8.5.2. By Country

9. Europe HER2 Antibodies Market Analysis and Forecast

  • 9.1. Introduction
  • 9.2. Key Findings
  • 9.3. Market Value Forecast, by Type of Treatment Drugs, 2020-2034
    • 9.3.1. Trastuzumab
    • 9.3.2. Lapatinib
    • 9.3.3. Ado-trastuzumab Emtansine
    • 9.3.4. Pertuzumab
    • 9.3.5. Everolimus
  • 9.4. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 9.4.1. Germany
    • 9.4.2. U.K.
    • 9.4.3. France
    • 9.4.4. Italy
    • 9.4.5. Spain
    • 9.4.6. Rest of Europe
  • 9.5. Market Attractiveness Analysis
    • 9.5.1. By Type of Treatment Drugs
    • 9.5.2. By Country/Sub-region

10. Asia Pacific HER2 Antibodies Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Type of Treatment Drugs, 2020-2034
    • 10.3.1. Trastuzumab
    • 10.3.2. Lapatinib
    • 10.3.3. Ado-trastuzumab Emtansine
    • 10.3.4. Pertuzumab
    • 10.3.5. Everolimus
  • 10.4. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 10.4.1. China
    • 10.4.2. Japan
    • 10.4.3. India
    • 10.4.4. Australia & New Zealand
    • 10.4.5. Rest of Asia Pacific
  • 10.5. Market Attractiveness Analysis
    • 10.5.1. By Type of Treatment Drugs
    • 10.5.2. By Country/Sub-region

11. Latin America HER2 Antibodies Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Type of Treatment Drugs, 2020-2034
    • 11.3.1. Trastuzumab
    • 11.3.2. Lapatinib
    • 11.3.3. Ado-trastuzumab Emtansine
    • 11.3.4. Pertuzumab
    • 11.3.5. Everolimus
  • 11.4. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.4.1. Brazil
    • 11.4.2. Mexico
    • 11.4.3. Rest of Latin America
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Type of Treatment Drugs
    • 11.5.2. By Country/Sub-region

12. Middle East & Africa HER2 Antibodies Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Type of Treatment Drugs, 2020-2034
    • 12.3.1. Trastuzumab
    • 12.3.2. Lapatinib
    • 12.3.3. Ado-trastuzumab Emtansine
    • 12.3.4. Pertuzumab
    • 12.3.5. Everolimus
  • 12.4. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.4.1. GCC Countries
    • 12.4.2. South Africa
    • 12.4.3. Rest of Middle East & Africa
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Type of Treatment Drugs
    • 12.5.2. By Country/Sub-region

13. Competition Landscape

  • 13.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 13.2. Market Share Analysis, by Company (2023)
  • 13.3. Company Profiles
    • 13.3.1. Novartis AG
      • 13.3.1.1. Company Overview
      • 13.3.1.2. Product Portfolio
      • 13.3.1.3. SWOT Analysis
      • 13.3.1.4. Financial Overview
      • 13.3.1.5. Strategic Overview
    • 13.3.2. Pfizer, Inc.
      • 13.3.2.1. Company Overview
      • 13.3.2.2. Product Portfolio
      • 13.3.2.3. SWOT Analysis
      • 13.3.2.4. Financial Overview
      • 13.3.2.5. Strategic Overview
    • 13.3.3. F. Hoffmann-La Roche Ltd.
      • 13.3.3.1. Company Overview
      • 13.3.3.2. Product Portfolio
      • 13.3.3.3. SWOT Analysis
      • 13.3.3.4. Financial Overview
      • 13.3.3.5. Strategic Overview
    • 13.3.4. Abnova Corporation
      • 13.3.4.1. Company Overview
      • 13.3.4.2. Product Portfolio
      • 13.3.4.3. SWOT Analysis
      • 13.3.4.4. Financial Overview
      • 13.3.4.5. Strategic Overview
    • 13.3.5. InvivoGen
      • 13.3.5.1. Company Overview
      • 13.3.5.2. Product Portfolio
      • 13.3.5.3. SWOT Analysis
      • 13.3.5.4. Financial Overview
      • 13.3.5.5. Strategic Overview
    • 13.3.6. Celltrion, Inc.
      • 13.3.6.1. Company Overview
      • 13.3.6.2. Product Portfolio
      • 13.3.6.3. SWOT Analysis
      • 13.3.6.4. Financial Overview
      • 13.3.6.5. Strategic Overview
    • 13.3.7. Biocon
      • 13.3.7.1. Company Overview
      • 13.3.7.2. Product Portfolio
      • 13.3.7.3. SWOT Analysis
      • 13.3.7.4. Financial Overview
      • 13.3.7.5. Strategic Overview
    • 13.3.8. Novus Biologicals
      • 13.3.8.1. Company Overview
      • 13.3.8.2. Product Portfolio
      • 13.3.8.3. SWOT Analysis
      • 13.3.8.4. Financial Overview
      • 13.3.8.5. Strategic Overview